DexCom, Inc. Forecasted to Post Q1 2018 Earnings of ($0.21) Per Share (NASDAQ:DXCM)
DexCom, Inc. (NASDAQ:DXCM) – Investment analysts at Northcoast Research issued their Q1 2018 earnings per share estimates for shares of DexCom in a research report issued to clients and investors on Wednesday. Northcoast Research analyst E. Snyder forecasts that the medical device company will post earnings per share of ($0.21) for the quarter. Northcoast Research also issued estimates for DexCom’s Q2 2018 earnings at ($0.04) EPS, Q3 2018 earnings at $0.05 EPS, Q4 2018 earnings at $0.16 EPS and FY2018 earnings at ($0.04) EPS.
DexCom (NASDAQ:DXCM) last released its earnings results on Tuesday, May 2nd. The medical device company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.06. DexCom had a negative net margin of 14.70% and a negative return on equity of 32.94%. The company had revenue of $142.30 million for the quarter, compared to analysts’ expectations of $143.94 million. TRADEMARK VIOLATION NOTICE: This story was published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/07/27/dexcom-inc-forecasted-to-post-q1-2018-earnings-of-0-21-per-share-nasdaqdxcm.html.
Several other research analysts also recently weighed in on the company. Cowen and Company reaffirmed an “outperform” rating and set a $90.00 target price on shares of DexCom in a research note on Tuesday, April 18th. BTIG Research downgraded DexCom from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 3rd. BidaskClub raised DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. William Blair reaffirmed an “outperform” rating on shares of DexCom in a research note on Thursday, April 27th. Finally, Jefferies Group LLC reduced their target price on DexCom to $91.00 and set a “buy” rating for the company in a research note on Tuesday, May 9th. One analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $89.47.
DexCom (DXCM) traded down 2.12% during midday trading on Thursday, reaching $67.29. 649,441 shares of the company’s stock were exchanged. DexCom has a 52 week low of $57.68 and a 52 week high of $96.38. The firm’s 50 day moving average is $72.79 and its 200 day moving average is $75.75. The firm’s market capitalization is $5.81 billion.
A number of hedge funds have recently modified their holdings of the stock. Livforsakringsbolaget Skandia Omsesidigt bought a new stake in shares of DexCom during the first quarter valued at about $136,000. IFP Advisors Inc boosted its stake in shares of DexCom by 9.3% in the first quarter. IFP Advisors Inc now owns 1,863 shares of the medical device company’s stock valued at $158,000 after buying an additional 159 shares during the last quarter. Edmond DE Rothschild Holding S.A. bought a new stake in shares of DexCom during the first quarter valued at about $164,000. Mn Services Vermogensbeheer B.V. boosted its stake in shares of DexCom by 3.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,254 shares of the medical device company’s stock valued at $179,000 after buying an additional 83 shares during the last quarter. Finally, Daiwa Securities Group Inc. boosted its stake in shares of DexCom by 475.0% in the first quarter. Daiwa Securities Group Inc. now owns 2,300 shares of the medical device company’s stock valued at $195,000 after buying an additional 1,900 shares during the last quarter.
In other DexCom news, CEO Kevin R. Sayer sold 8,649 shares of the company’s stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $68.39, for a total value of $591,505.11. Following the completion of the sale, the chief executive officer now directly owns 347,329 shares in the company, valued at approximately $23,753,830.31. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Andrew K. Balo sold 3,200 shares of the company’s stock in a transaction on Wednesday, May 10th. The shares were sold at an average price of $71.93, for a total value of $230,176.00. The disclosure for this sale can be found here. Insiders have sold 36,331 shares of company stock valued at $2,548,619 over the last quarter. 1.70% of the stock is owned by company insiders.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.